Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Plans for a hand-held PlayStation device show the game isn’t really about selling units anymore, it’s about hoarding consumers’ attention.
Gavin Newsom said the Golden State “will intervene” and provide rebates to residents on its own if the tax credit goes the way of the Fisker.
Ford may want to authenticate your face when you get behind the wheel.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Three major event films — Wicked, Gladiator II, and Moana 2 — set to dominate multiplex screens this Thanksgiving week.
Novartis is banking on the startup’s promising treatment candidates for neuromuscular diseases, many of which are genetic in nature.
Bribe locally, fundraise globally. That pretty much sums up the business ethos of billionaire Gautam Adani as laid out by US prosecutors.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Military tech startups are seeing a big boost in their valuations of late, spurred in part by former President Trump’s re-election.
Walmart announced that it’s raising its outlook for the year, thanks in part to a rocking start to the holiday shopping season.
Will generative artificial intelligence’s star be added to the Hollywood Walk of Fame? Andreessen Horowitz sure thinks so.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.